Evolus, Inc. — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 72/100
What the filing says
Evolus entered into three major exclusive distribution agreements: (1) a U.S. license with IBSA (Switzerland) for hyaluronic acid injectables (Profhilo brand) effective July 7, 2026, with 15-year term and minimum purchase requirements starting Year 4; (2) a European expansion agreement (August 3, 2026) adding Canada, Australia, and New Zealand to Evolus Pharma B.V.'s existing European territory, with royalties and milestone payments (signing and registration payments redacted); and (3) a U.S. amendment (August 3, 2026) adjusting minimum purchase requirements. All specific financial terms, royalty rates, transfer prices, and milestone amounts are redacted as competitively sensitive. The agreements establish exclusive rights in multiple territories with renewal provisions and development/regulatory obligations.
Why this rating
Exclusive multi-territory distribution rights for established product line expands addressable market significantly; 15-year terms provide revenue predictability; though financial detail redacted, this represents material geographic expansion and new revenue stream relative to $560M market cap.
Price action (we called it positive)
before filing · preread $6.67 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.